RNA repair restores hemoglobin expression in IVS2–654 thalassemic mice

Saovaros Svasti^{a,b,1}, Thipparat Suwanmanee^{a,1}, Suthat Fucharoen^b, Hong M. Moulton^c, Michelle H. Nelson^c, Nobuyo Maeda^d, Oliver Smithies^{d,2}, and Ryszard Kole^{a,c,2}

^aDepartment of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599; ^bThalassemia Research Center, Institute of Science and Technology for Research and Development, Mahidol University, Salaya Campus, Nakornpathom 73170, Thailand; ^cAVI BioPharma, Corvallis, OR 97333; and ^dDepartment of Pathology, University of North Carolina, Chapel Hill, NC 27599

Contributed by Oliver Smithies, December 8, 2008 (sent for review June 3, 2008)

Repair of β -globin pre-mRNA rendered defective by a thalassemia-causing splicing mutation, IVS2–654, in intron 2 of the human β -globin gene was accomplished in vivo in a mouse model of IVS2–654 thalassemia. This was effected by a systemically delivered splice-switching oligonucleotide (SSO), a morpholino oligomer conjugated to an arginine-rich peptide. The SSO blocked the aberrant splice site in the targeted pre-mRNA and forced the splicing machinery to reselect existing correct splice sites. Repaired β -globin mRNA restored significant amounts of hemoglobin in the peripheral blood of the IVS2–654 mouse, improving the number and quality of erythroid cells.

oligonucleotides | RNA splicing | thalassemia | therapy | morpholino oligomers

One of the most common inherited diseases, β -thalassemia, is caused by defects in the β -globin gene that affect production of β -globin, a subunit of hemoglobin (1). Current therapy consists of frequent blood transfusions combined with iron chelation (2). The only cure, bone marrow transplantation, is limited by the scarcity of suitable histocompatible donors (3). Although more than 200 mutations cause the disease, some of the most common ones induce aberrant splicing of β -globin pre-mRNA, interfering with proper translation of β -globin protein. The IVS2–654 (C > T) mutation creates an aberrant 5' splice site and activates a cryptic 3' splice site within intron 2 of the β -globin pre-mRNA, leading to retention of the intron fragment in the spliced mRNA even though the correct splice sites remain undamaged and potentially functional (Fig. 1A) (4). The retained fragment prevents proper translation of β -globin, leading to hemoglobin deficiency and β -thalassemia. The IVS2–654 mutation is a common cause of thalassemia in Thailand and other countries of Southeast Asia (5). Work in this laboratory showed that splice-switching oligonucleotides (SSOs), which block aberrant splice sites in IVS2–654 and other pre-mRNAs (IVS1–5, IVS1–6, IVS1–110, IVS2–705, and IVS2–745) as well as in the coding sequence (HbE) of the β -globin gene, force the splicing machinery to reselect the existing correct splice sites, repairing the splicing pattern of β -globin pre-mRNA. This repair, which restores production of correctly spliced β -globin mRNA and protein, was accomplished in several in vitro systems and ex vivo in erythroid progenitor cells from thalassemic patients (6–12). In this study, we investigated the effectiveness in thalassemic splicing correction of a modified morpholino oligomer, SSO 654-P005, in a mouse model of IVS2–654 β -thalassemia.

Results and Discussion

To be effective in splicing repair, SSOs must hybridize tightly to the targeted splicing elements, such as aberrant splice sites, and prevent their recognition by the splicing factors. Furthermore, the resulting double-stranded structures must not be recognized by RNase H, which degrades RNA in RNA-DNA duplexes (13). These conditions are satisfied in cell culture and in vivo by

modified oligomers with various backbones, including 2'-O-methoxyethyl phosphorothioate (MOE), locked nucleic acid (LNA), peptide nucleic acid conjugated with four lysines (PNA-4K), and phosphorodiamidate morpholino oligomers (14–16). However, MOE and LNA SSOs were ineffective at correcting aberrant splicing of IVS2–654 pre-mRNA when delivered ex vivo to cultured erythroid progenitor cells from IVS2–654 murine bone marrow cells (data not shown). PNA-4K and morpholino SSOs had only a modest effect at 45 μ M on IVS2–654 pre-mRNA splicing in these cells (Fig. 1B and C). Clearly, cell uptake of these oligonucleotides followed by translocation from the cytoplasm to the nucleus, the site of splicing, was limited. In this investigation, we found that a morpholino oligomer conjugated to a cell-penetrating peptide P005 (SSO 654-P005; in short is SSO P005) (17) was effective in a previously developed cell-based assay (18) and also in IVS2–654 pre-mRNA repair in cultured murine erythroid progenitor cells.

The shift in splicing from aberrant to correct was almost complete at 15 μ M SSO 654-P005 (Fig. 1D). This SSO was then used for treatment of the previously generated thalassemic IVS2–654 mice (19). These mice are heterozygotes with 1 human IVS2–654 thalassemic β -globin gene “knocked-in” to replace 2 *cis*- β -globin genes that code for murine adult β -globin (β -major and β -minor). The average level of total hemoglobin in these mice is 11.7 ± 0.5 g/dL ($n = 18$). Despite a relatively high level of total hemoglobin, these mice exhibit thalassemic characteristics, including abnormal hematological indices, splenomegaly and iron deposits in advanced age. This phenotype is somewhat different from that of humans, who, as heterozygotes, are essentially symptom-free but similar to other thalassemic mouse models. IVS–654 mice produce reduced amounts of murine β -globin chains, leading to imbalance of α - to β -globin production, which may be damaging to erythroid cells (19 and references cited therein).

The IVS2–654 mice were treated with SSO 654-P005, delivered intravenously at 25 mg/kg with 4 once-daily injections followed by a 3-day break for 3 weeks (*Materials and Methods*). This treatment restored correctly spliced human β -globin mRNA in the peripheral blood up to $\approx 12\%$ (Fig. 2A). The scrambled negative control SSO, P005 scr SSO, yielded no correction (Fig. 2A, lanes 6 and 7). Quantification of in vivo mRNA repair in the peripheral blood of SSO 654-P005-treated mice ($n = 3$ –4) using RT-quantitative real-time PCR (qPCR)

Author contributions: S.S., T.S., and R.K. designed research; S.S., T.S., H.M.M., and M.H.N. performed research; H.M.M., M.H.N., and N.M. contributed new reagents/analytical tools; S.S., T.S., S.F., H.M.M., N.M., O.S., and R.K. analyzed data; and S.S., T.S., S.F., O.S., and R.K. wrote the paper.

Conflict of interest statement: H.M.M., M.H.N., and R.K. are employed by AVI Biopharma, Inc.

¹S.S. and T.S. contributed equally to this work.

²To whom correspondence may be addressed. E-mail: rkole@avibio.com or langenbach@med.unc.edu.

© 2009 by The National Academy of Sciences of the USA

Fig. 1. (A) Splicing of IVS2-654 β -globin pre-mRNA and its repair by SSO. Boxes, exons; solid lines, introns and correct splicing pathway; dotted lines, aberrant splicing pathway. Thick bar, SSO; arrows, primers used in the RT-PCR assay. The length (in nucleotides) of RT-PCR products representing aberrantly (ab) and correctly (c) spliced mRNAs is shown. (B-D) Restoration of correctly spliced human β -globin mRNA in cultured erythroid progenitor cells. Cells were isolated from the bone marrow of IVS2-654 mouse and treated with PNA-4K (B), morpholino (C), and SSO P005 (D) SSOs. Treatment was by free uptake (FU) of SSO from the culture medium. SSO concentrations and the time of cell harvest are indicated. Total cellular RNA was analyzed by RT-PCR. N, RNA from normal human blood.

showed that the correct human β -globin mRNA was restored up to 6-fold after treatment (Fig. 2B). The newly repaired β -globin mRNA was properly translated in circulating red blood cells (RBCs) and consistently yielded chimeric mouse-human hemoglobin ($\alpha\alpha\text{h}\beta_2$), which reached $\approx 1\text{--}5\%$ of the total in treated mice ($n = 9$; Fig. 2C).

Analysis of RBCs was carried out on mice 834, 835, 843, and 845. Despite a relatively low level of hemoglobin expression (Fig. 2C, lanes 4–7), improvement in RBC morphology was clearly detectable. Abnormal RBCs, including fragmented cells and those with abnormalities in shape and size (poikilocytosis and anisocytosis), were much less evident, indicating more effective erythropoiesis and less extravascular hemolysis. Concomitantly, the number of normal RBCs increased by $\approx 10\%$ (Fig. 3A and B). These results were consistent with a detectable and statistically significant reduction of the red cell distribution width (RDW), an indicator of red cell heterogeneity and increase in total hemoglobin level in the peripheral blood ($n = 5$; Fig. 4) of treated mice 5, 6, 13, 995, and 996 (Fig. 2C, lanes 8–12). In each mouse, the trend was reduced RDW and increased hemoglobin

Fig. 2. Repair of human β -globin mRNA in vivo in IVS2–654 thalassemic mice by i.v. injections of SSO P005. (A) Conventional RT-PCR of total RNA from SSO P005-treated mice. RNA was isolated from peripheral blood. Lane 1, normal human blood (N); lane 2, prebleed; lanes 3–5, blood collected after 4, 8, and 12 SSO injections, respectively; lanes 6–7, blood collected from IVS2–654 mice treated with negative control P005 scr SSO; lane 8, no reverse transcription (NRT); lane 9, no template control (NTC). Days of bleeding and percentages of correctly (c) spliced mRNA compared with aberrantly (ab) spliced mRNA are indicated. No product was detectable without the RT step or in the absence of mRNA template. (B) Quantification of RNA repair by RT-qPCR. The mice were prebled and intravenously injected with 4 ($n = 4$), 8 ($n = 3$), and 12 ($n = 3$) doses of SSO P005. Total RNA from blood collected before [day (d) 0] and after every 4 SSO injections (d 5, 12, and 19) was analyzed. Data presented as mean $\pm$ SD. P values <0.05 were determined by one-way ANOVA. Asterisks denote statistically significant difference. The correctly spliced human β -globin mRNA was not detectable (ND) in prebled samples because the probe was designed to hybridize exclusively to the correct human β -globin mRNA (*Materials and Methods*). (C) Chimeric mouse-human hemoglobin ($\text{ma}_2\beta_2$) generated by SSO P005 treatment. IVS2–654 mice ($n = 9$) were dosed intravenously with SSO P005 for 3 weeks on a schedule: 4 once-daily injections and 3 days off. (Top) Hemoglobin levels were assayed by immunoblots with anti-human β -globin antibody of cellulose acetate electrophoregrams. Blood samples were taken before injections (lanes 1–3) and 1 day after the last injection (d 19) (lanes 4–12). (Bottom) Immunoblots were quantified using ImageQuant TL software.

level, whereas in saline-treated mice, this trend was not observed. It is also noticeable that in mice with a lower initial hemoglobin level (≤ 11 g/dL), the increase was more pronounced (Fig. 4B).

The latter observation was confirmed in a single IVS2–654 mouse encountered in the colony with a low total hemoglobin level of 7.5 g/dL. We took advantage of this mouse and subjected it to an extended course of SSO 654-P005 treatment delivered by i.p. injection at 50 mg/kg on a schedule 4 days on and 3 days off for 6 weeks. In this particular experiment, the SSO treatment led

Fig. 3. Improvement of RBC morphology after SSO P005 treatment. (A) Wright-Giemsa-stained peripheral blood smears of IVS2-654 mouse were prepared before [day (d) 0] and after 12 i.v. injections of SSO P005 (d 19). WT, wild-type mouse. (B) Differential count of abnormal (ARBC), target (TRBC), hypochromic (HRBC), and normal (NRBC) RBCs. Blood smears before and after 12 i.v. injections of SSO P005 from IVS2-654 mice ($n = 4$) were stained with Wright-Giemsa. Three different field images were taken from each smear and used for the differential RBC count. Data are presented as mean $\pm$ SD. The difference between the numbers of NRBCs before and after SSO P005 treatment is 10% but not significant ($P = 0.06$; one-tailed Wilcoxon signed test).

to marked elevation of hemoglobin from 7.5 to 10.7 g/dL and of hematocrit levels from 19.9 to 29% (data not shown). Although a single mouse experiment has no statistical value, it further supports the notion that prolonged SSO treatment may be clinically valuable. It also suggests that at low hemoglobin levels, the response may be more robust than in mice with relatively high levels of hemoglobin. Thus, the nature of the model could have contributed to the modest response to treatment shown in Fig. 4.

This treatment was terminated at day 19 because we were unable to inject SSO 654-P005 into scarred tail veins reliably. Note that mouse RBCs have a lifespan of ≈ 60 days (20). Thus, during the period of injections, even if the restoration of splicing and hemoglobin production were 100% effective, only one-third of the existing RBCs, lacking additional hemoglobin, could have been replaced. Nevertheless, with prolonged SSO treatment, the fraction of healthy RBCs should continue to increase in the cell population in peripheral blood and further improve the overall hematological manifestations, including elevation of the hemoglobin and hematocrit levels.

We investigated the toxicity of SSO 654-P005 in IVS2-654 mice ($n = 4$) that received 16 SSO injections. Standard biochemical tests indicate no apparent liver or kidney toxicity (Fig. 5A–D), nor was there any weight loss (Fig. 5E). To evaluate the primary inflammatory response that the treated mice might develop against the peptide-conjugated SSO 654-P005, we performed RT-qPCR to determine the change in transcriptional level of the IFN- γ and IL-12 α cytokines after every 4 i.v. injections of the SSO at 25 mg/kg. The results shown in Fig. 5F indicate no significant change in the mRNA level of both

cytokines. Furthermore, we found no significant change in IL-12 cytokines in SSO 654-P005-primed mice when they were challenged with the SSO 1 month after treatment, indicating that the SSO did not trigger the immune functioning cells to release their inflammatory cytokine (Table 1). More importantly, we did not detect SSO 654-P005-specific antibodies in the sera, indicating that the SSO did not induce a humoral immune response (data not shown). Finally, we investigated the cellular immune response of the lymphocytes from the treated mice to indicate whether they form memory cells that can recognize the SSO. To this end, we used the enzyme-linked immunosorbent spot assay (ELISPOT) to monitor the IFN- γ production and SSO 654-P005-specific antibody induction in the cultured lymphocytes that ex vivo encountered the SSO 654-P005. We found that the SSO challenge did not stimulate the lymphocytes to produce either IFN- γ or the antibody (data not shown).

We have found that repair of splicing-defective thalassemic pre-mRNA and concomitant production of adult hemoglobin (HbA) can be accomplished ex vivo in erythroid progenitor cells from thalassemic patients treated with SSOs with modified backbones (10, 11), including peptide-conjugate morpholino, SSO 654-P005 (data not shown). Thus, this treatment is compatible with and effective in the human cells that will constitute its target in the clinic.

We have shown by several measures that SSO 654-P005 improved the efficiency of erythropoiesis and concomitant morphology of erythrocytes in the peripheral blood of treated thalassemic mice. The SSO-induced mRNA repair, production of human β -globin, more efficient cell hemoglobinization, increased number of improved mature erythrocytes, and small

Fig. 4. Blood analysis for red cell heterogeneity (A) and hemoglobin level (B). Blood samples from IVS2-654 mice before (prebleed) and after treatment with 12 i.v. injections of SSO P005 ($n = 5$) were analyzed in Heksa's animal blood counter. Asterisk indicates statistically significant (one-tailed Wilcoxon signed test) difference between prebleed and SSO P005-treated mice. (A and B) $P = 0.03$. (C and D) RDW and hemoglobin levels of WT mice ($n = 3$) injected with saline (mean $\pm$ SD).

increase in the total level of hemoglobin were consistently evident after treatment, confirming that it had beneficial effects.

The fact that the effects were modest may reflect the nature of the model more than the performance of the oligonucleotide. The IVS2-654 mice are heterozygotes; therefore, at best, SSO treatment may only increase the hemoglobin levels by no more than one-half. Because the duration of the experiment was 19 days (i.e., one-third of the murine erythrocyte 60-day lifespan), the effect is reduced to $\approx 15\%$, assuming complete IVS2-654 repair in all targetable erythroid progenitor cells. SSO effectiveness less than 100%, which is to be expected, brings the results within statistical error, which, in our hands, was about 10% for hemoglobin and hematocrit assay. Furthermore, these calculations do not take into account that IVS2-654 gene may be expressed at a level that produced less mRNA, and hence β -globin, than the combined output of eliminated mouse β -major and β -minor genes. Another contributing factor to the poor response of the model appears to be the relatively high (11.7 g/dL) preexisting level of hemoglobin in untreated thalassemic mice. This is supported by the observation that in a mouse that had low hemoglobin (i.e., more pronounced anemia) and was treated with SSO 654-P005 for 6 weeks, the response was much more robust. Because the SSO is effective in human cells, the approach may be applicable to patients with IVS2-654/HbE thalassemia who do not produce functional HbA.

One notes that in transfused thalassemics, the hemoglobin level rises to about 20–30% and is clinically sufficient, whereas carriers with 50% hemoglobin are essentially asymptomatic. The results of this work already showed changes in blood morphology; the improvements need not be dramatic to achieve clinical significance. It is possible that continuous i.v. injections, impossible in mice for technical reasons, may be sufficient. The dose of SSO 654-P005 appears high at 25 mg/kg. However, if, as is frequently the case, dosing of morpholino oligonucleotides is scaled between mice and humans by mg/m^2 , the human equivalent dose would be 2 mg/kg, which translates into 100 mg per dose for a 50-kg child, a likely patient.

Fig. 5. Toxicity assay of SSO P005. Serum samples from IVS2-654 mice before [day (d) 0] and after treatment with 16 i.v. injections (d 26) of saline ($n = 5$) or SSO P005 ($n = 4$) were analyzed for (A) aspartate aminotransferase (AST, U/L), (B) alanine aminotransferase (ALT, U/L), (C) blood urea nitrogen (BUN, mg/dL), and (D) creatinine (CREA, mg/dL). (E) Body weights of the mice were recorded before (d 0) and after every 4 i.v. injections (d 5, 12, 19, and 26) of saline ($n = 5$) or SSO P005 ($n = 4$). (F) Quantification of cytokine mRNAs by RT-qPCR. The peripheral blood RNAs from saline mice ($n = 3$) and mice treated with 4 ($n = 5$), 8 ($n = 6$), and 12 ($n = 4$) injections of SSO P005 were analyzed for IFN- γ and IL-12a mRNAs. Data presented as mean $\pm$ SD.

Recent reports showed in vivo restoration of chloride channel function in myotonic dystrophy (21), factor VIII in a model of hemophilia (22), and dystrophin in the *mdx* mouse model of Duchenne muscular dystrophy (23–25) by oligonucleotide-induced modulation of splicing, an approach discovered in the Kole laboratory (6). These results, together with those reported here, indicate that the splicing-mediated pre-mRNA repair is not limited to a single disease. In fact, modulation of aberrant and alternative splicing by antisense oligonucleotides is likely to be useful in numerous indications, because 70% of human genes are alternatively spliced, with a number of them associated with cancer (26) and other diseases (27–29).

Materials and Methods

Oligonucleotides. The profiles of morpholino and PNA-4K oligonucleotides, including their sequences, were reported elsewhere (11, 14, 15). The 18-mer morpholino (5'-GCTATTACCTTAACCCAG-3')-peptide-[(D)(R)RRQRKRFFC] conjugate (P005) antisense to the aberrant 5' splice site in the IVS2-654 β -globin pre-mRNA was synthesized at AVI BioPharma. The peptide contained 2 D-amino acid arginines at its N terminus as indicated in the sequence. The peptide was conjugated at the 5' end of the morpholino oligomer through a noncleavable linker. The method for synthesis and purification of the conju-

Samples	Preboosting	Day 3	Day 7	Day 28
Sal + Sal (7*)	0.67	28.49	ND	0.41
Sal + Sal (14*)	ND	ND	ND	0.21
Sal + Sal (998*)	ND	ND	ND	1.8
SSO + Sal (5 [†])	5.94	1.25	4.77	3.3
SSO + Sal (13 [†])	ND	ND	ND	ND
SSO + SSO (6 [‡])	ND	0.41	ND	ND
SSO + SSO (995 [‡])	ND	ND	ND	ND
SSO + SSO (996 [‡])	2.42	30.84	1.55	2.72

ND, not detectable.

compared using one-way ANOVA. Data with a *P* value <0.05 were considered statistically significant.

ACKNOWLEDGMENTS. We thank Elizabeth Smith and Brian Buckley for excellent technical assistance. We gratefully acknowledge Ande West for

her help in the immune response study. This work was supported by National Institutes of Health grants GM 59299 and 5R42-HL078103 (to R.K.) and by grants from the Thailand Research Fund (S.F. and S.S.). S.S. and T.S. were supported in part by the Cooley's Anemia Foundation.

- Gibbons R, Higgs DR, Olivieri NF, Wood WG (2001) *The Thalassemia Syndromes*, eds Weatherall DJ, Clegg JB (Blackwell Science, Oxford), pp 287–356.
- Old JM, Olivieri NF, Thein SL (2001) *The Thalassemia Syndromes*, eds Weatherall DJ, Clegg JB (Blackwell Science, Oxford), pp 630–685.
- Lucarelli G, et al. (1999) Bone marrow transplantation in adult thalassemic patients. *Blood* 93:1164–1167.
- Cheng TC, et al. (1984) beta-Thalassemia in Chinese: Use of in vivo RNA analysis and oligonucleotide hybridization in systematic characterization of molecular defects. *Proc Natl Acad Sci USA* 81:2821–2825.
- Fucharoen S, Winichagoon P (1997) Hemoglobinopathies in Southeast Asia: Molecular biology and clinical medicine. *Hemoglobin* 21:299–319.
- Dominski Z, Kole R (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. *Proc Natl Acad Sci USA* 90:8673–8677.
- Sierakowska H, Sambade MJ, Agrawal S, Kole R (1996) Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. *Proc Natl Acad Sci USA* 93:12840–12844.
- Schmajuk G, Sierakowska H, Kole R (1999) Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. *J Biol Chem* 274:21783–21789.
- Sierakowska H, Sambade MJ, Schumperli D, Kole R (1999) Sensitivity of splice sites to antisense oligonucleotides in vivo. *RNA* 5:369–377.
- Lacerra G, et al. (2000) Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. *Proc Natl Acad Sci USA* 97:9591–9596.
- Suwanmanee T, et al. (2002) Restoration of human beta-globin gene expression in murine and human IVS2–654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. *Mol Pharmacol* 62:545–553.
- Suwanmanee T, Sierakowska H, Fucharoen S, Kole R (2002) Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder. *Mol Ther* 6:718–726.
- Crooke ST, Vickers T, Lima W, Wu H (2008) *Antisense Drug Technology: Principles, Strategies, and Applications*, ed Crooke ST (CRC Press, Boca Raton, FL), pp 3–46.
- Sazani P, et al. (2001) Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. *Nucleic Acids Res* 29:3965–3974.
- Sazani P, et al. (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. *Nat Biotechnol* 20:1228–1233.
- Roberts J, et al. (2006) Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. *Mol Ther* 14:471–475.
- Moulton HM, Hase MC, Smith KM, Iversen PL (2003) HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. *Antisense Nucleic Acid Drug Dev* 13:31–43.
- Kang SH, Cho MJ, Kole R (1998) Up-regulation of luciferase gene expression with antisense oligonucleotides: Implications and applications in functional assay development. *Biochemistry* 37:6235–6239.
- Lewis J, et al. (1998) A common human beta globin splicing mutation modeled in mice. *Blood* 91:2152–2156.
- Kean LS, et al. (2002) Comparison of mechanisms of anemia in mice with sickle cell disease and beta-thalassemia: Peripheral destruction, ineffective erythropoiesis, and phospholipid scramblase-mediated phosphatidylserine exposure. *Exp Hematol* 30:394–402.
- Wheeler TM, et al. (2007) Correction of CIC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. *J Clin Invest* 117:3952–3957.
- Chao H, et al. (2003) Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. *Nat Med* 9:1015–1019.
- Wilton SD, et al. (1999) Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. *Neuromuscul Disord* 9:330–338.
- Alter J, et al. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. *Nat Med* 12:175–177.
- Jearawiriyapaisarn N, et al. (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. *Mol Ther*, in press.
- Mercatante DR, Kole R (2002) Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: Effects on gene expression. *Biochim Biophys Acta* 1587:126–132.
- Sazani P, Kole R (2003) Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. *J Clin Invest* 112:481–486.
- Sazani P, Graziewicz MA, Kole R (2008) *Antisense Drug Technology: Principles, Strategies, and Applications*, ed Crooke ST (CRC Press, Boca Raton, FL), pp 89–114.
- Graziewicz MA, et al. (2008) An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. *Mol Ther* 16:1316–1322.